145 related articles for article (PubMed ID: 2681554)
1. Ifosfamide plus doxorubicin in metastatic adult sarcomas: a multi-institutional phase II trial.
Loehrer PJ; Sledge GW; Nicaise C; Usakewicz J; Hainsworth JD; Martelo OJ; Omura G; Braun TJ
J Clin Oncol; 1989 Nov; 7(11):1655-9. PubMed ID: 2681554
[TBL] [Abstract][Full Text] [Related]
2. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
Lorigan P; Verweij J; Papai Z; Rodenhuis S; Le Cesne A; Leahy MG; Radford JA; Van Glabbeke MM; Kirkpatrick A; Hogendoorn PC; Blay JY;
J Clin Oncol; 2007 Jul; 25(21):3144-50. PubMed ID: 17634494
[TBL] [Abstract][Full Text] [Related]
3. A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas.
Bokemeyer C; Franzke A; Hartmann JT; Schöber C; Arseniev L; Metzner B; Link H; Kanz L; Schmoll HJ
Cancer; 1997 Oct; 80(7):1221-7. PubMed ID: 9317171
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Santoro A; Tursz T; Mouridsen H; Verweij J; Steward W; Somers R; Buesa J; Casali P; Spooner D; Rankin E
J Clin Oncol; 1995 Jul; 13(7):1537-45. PubMed ID: 7602342
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
[TBL] [Abstract][Full Text] [Related]
6. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy.
Elias A; Ryan L; Sulkes A; Collins J; Aisner J; Antman KH
J Clin Oncol; 1989 Sep; 7(9):1208-16. PubMed ID: 2504890
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin, ifosfamide, and dacarbazine (AID) with mesna uroprotection for advanced untreated sarcoma: a phase I study.
Elias AD; Antman KH
Cancer Treat Rep; 1986 Jul; 70(7):827-33. PubMed ID: 3087617
[TBL] [Abstract][Full Text] [Related]
8. Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).
Maurel J; Fra J; López-Pousa A; García del Muro X; Balañá C; Casado A; Martín J; Martínez-Trufero J; de las Peñas R; Buesa JM;
Cancer; 2004 Apr; 100(7):1498-506. PubMed ID: 15042685
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas.
Nielsen OS; Reichardt P; Christensen TB; Pink D; Daugaard S; Hermans C; Marreaud S; van Glabbeke M; Blay J; Judson I
Eur J Cancer; 2006 Sep; 42(14):2303-9. PubMed ID: 16891112
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group.
Le Cesne A; Judson I; Crowther D; Rodenhuis S; Keizer HJ; Van Hoesel Q; Blay JY; Frisch J; Van Glabbeke M; Hermans C; Van Oosterom A; Tursz T; Verweij J
J Clin Oncol; 2000 Jul; 18(14):2676-84. PubMed ID: 10894866
[TBL] [Abstract][Full Text] [Related]
11. Treatment of advanced soft tissue sarcomas with ifosfamide and doxorubicin combination chemotherapy.
Barişta I; Tekuzman G; Yalçin S; Güllü I; Güler N; Ozişik Y; Kars A; Celik I; Türker A; Altundağ K; Zengin N; Uner A; Baltali E; Firat D
J Surg Oncol; 2000 Jan; 73(1):12-6. PubMed ID: 10649272
[TBL] [Abstract][Full Text] [Related]
12. Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group.
Schütte J; Mouridsen HT; Stewart W; Santoro A; van Oosterom AT; Somers R; Blackledge G; Verweij J; Dombernowsky P; Thomas D
Eur J Cancer; 1990; 26(5):558-61. PubMed ID: 2144740
[TBL] [Abstract][Full Text] [Related]
13. Ifosfamide plus doxorubicin in previously untreated patients with advanced soft-tissue sarcoma.
Schütte J; Mouridsen HT; Steward W; Santoro A; van Oosterom AT; Somers R; Blackledge G; Verweij J; Dombernowsky P; Thomas D
Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S204-9. PubMed ID: 8453699
[TBL] [Abstract][Full Text] [Related]
14. Dana-Farber Cancer Institute studies in advanced sarcoma.
Antman KH; Elias A
Semin Oncol; 1990 Feb; 17(1 Suppl 2):7-15. PubMed ID: 2106162
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas.
De Pas T; Curigliano G; Masci G; Catania C; Comandone A; Boni C; Tucci A; Pagani O; Marrocco E; de Braud F;
Ann Oncol; 2002 Jan; 13(1):161-6. PubMed ID: 11863099
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of ifosfamide/mesna with doxorubicin for adult soft tissue sarcoma.
Cantwell BM; Carmichael J; Ghani S; Harris AL
Cancer Chemother Pharmacol; 1988; 21(1):49-52. PubMed ID: 3124971
[TBL] [Abstract][Full Text] [Related]
17. Optimizing clinical care in patients with advanced soft tissue sarcoma: a phase II study of a new schedule of high-dose continuous infusion ifosfamide and doxorubicin combination.
De Pas T; Rosati G; Spitaleri G; Boni C; Tucci A; Frustaci S; Scalamogna R; Radice D; Boselli S; Toffalorio F; Catania C; Noberasco C; Delmonte A; Vecchio F; de Braud F
Chemotherapy; 2011; 57(3):217-24. PubMed ID: 21597285
[TBL] [Abstract][Full Text] [Related]
18. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas.
Patel SR; Vadhan-Raj S; Burgess MA; Plager C; Papadopolous N; Jenkins J; Benjamin RS
Am J Clin Oncol; 1998 Jun; 21(3):317-21. PubMed ID: 9626808
[TBL] [Abstract][Full Text] [Related]
19. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
Edmonson JH; Ryan LM; Blum RH; Brooks JS; Shiraki M; Frytak S; Parkinson DR
J Clin Oncol; 1993 Jul; 11(7):1269-75. PubMed ID: 8315424
[TBL] [Abstract][Full Text] [Related]
20. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
Antman K; Crowley J; Balcerzak SP; Rivkin SE; Weiss GR; Elias A; Natale RB; Cooper RM; Barlogie B; Trump DL
J Clin Oncol; 1993 Jul; 11(7):1276-85. PubMed ID: 8315425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
